Solomon Moshkevich

NTRA president sells 3,000 shares for $655,294.81 under 10b5-1 plan; stock now -17.4% from 52-week high

Solomon Moshkevich, president of ClinicalDiagnostics at Natera, executed 4 separate sales totaling 3,000 shares for $655,294.81 at prices ranging from $217.52 to $220.67 on 2026-06-01, reducing his holdings by 2.1% to 137,643 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, making it scheduled rather than discretionary. The current stock price of $211.85 reflects a -17.4% decline from the 52-week high of $256.36, and while the company reported strong annual revenue growth of +35.9%, it remains unprofitable with a net income of $-85.1M in the latest full fiscal year. Investors should note the non-discretionary nature of this sale and the company's unprofitable status despite robust top-line growth.

President of Clinical Diagnostics sells $693,560 in Natera stock, continuing a 102-trade pattern of open-market dispositions with poor historical timing.

Moshkevich Solomon, President of Clinical Diagnostics at Natera, sold approximately $694,000 in shares across seven tranches in a single day, reducing his holding by less than 2.5 percent. This filing continues an extreme pattern: across a 36-month window, Solomon has executed 102 open-market sales and zero open-market purchases—pure selling with no buying activity whatsoever. At this specific ticker, his five prior sales were uniformly poorly timed, with the stock rising after each exit, suggesting he has not successfully predicted price movements in Natera stock historically. The company remains unprofitable despite strong revenue growth, and the stock currently trades well below its 52-week high. While the sale itself is modest relative to his holdings, the relentless execution of sell-only activity by someone in operational leadership over three years, combined with a track record of selling into subsequent rallies, warrants attention as a potential signal of sustained insider skepticism about near-term prospects.

NTRA President Solomon Moshkevich sold 3,000 shares across 3 transactions for $606,899.48; holds 147.9K shares post-sale

Moshkevich executed three separate sales on 2026-04-01 at prices ranging from $201.32 to $203.31, generating $606,899.48 at a blended average of $202.30. This represents a 2.0% reduction of his holdings (from 150.9K to 147.9K shares). His same-ticker history at NTRA shows 5 prior sales, with recent trades on 2026-03-02 showing modest 30-day positive returns (+1.1% to +2.2%), while earlier February sales posted negative 30-day returns (-12.0% to -14.6%). His cross-ticker track record demonstrates strong timing discipline with a 100.00% well-timed rate across 20 prior sells (avg 90d return -12.2%), though notably none of his NTRA-specific prior sales have yet reached measurable 90-day outcomes. Natera remains unprofitable (net income $-87.5M on revenue $592.2M) despite strong annual revenue growth of +35.9%, providing context for insider activity at a high-growth biotech generating significant losses.

President of Clinical Diagnostics sells 3,000 NTRA shares for $599,545.06; stock down 10.4% in 30 days, company unprofitable.

Moshkevich Solomon, President of Clinical Diagnostics, executed 3 separate sales totaling 3,000 shares for $599,545.06 on 2026-03-02 at a blended average price of $199.85. The stock has since declined 10.4% over 30 days and 13.1% over 90 days from the current price of $207.04, trading at 18.6% below its 52-week high of $254.40. His holding of 150,023 shares post-transaction represents a 2.0% reduction from prior holdings. Notably, NTRA remains unprofitable with negative net income of $-87,544,000.00 in the latest quarter, despite strong annual revenue growth of 35.9%, providing context for insider liquidity decisions in a high-growth but currently loss-making enterprise.

NTRA President sells 4,639 shares across 7 transactions for $1.1M at $231.20 avg; stock down 19.2% from high

Moshkevich Solomon, President of Clinical Diagnostics at Natera, executed 7 separate sales totaling 4,639 shares for $1,072,537.92 on February 2–3, 2026, at a blended average price of $231.20. The transactions represent a 3.3% reduction in his holdings (142.5K shares pre-transaction to 137.8K post-transaction). The sale occurred as the stock has declined 19.2% from its 52-week high and 13.4% over the past 30 days, though the company posted strong annual revenue growth of +56.8% and a substantial $28.4B market cap. The company remained unprofitable with net income of -$87.5M in the latest period, creating a backdrop of strong growth but persistent losses. His same-ticker sales history shows 4 recent sales in January (outcomes not yet measurable) plus one prior sale on 2026-01-02 with a modest +0.8% 30-day return, with no well-timed outcomes yet measured at the 90-day level at this ticker.

Moshkevich (NTRA President) sold 2,213 shares for $528,853.09 across 2 trades, retaining 142,486 shares post-sale.

Moshkevich executed 2 separate sales totaling 2,213 shares for $528,853.09, representing a 1.5% reduction from his 144,699-share pre-transaction position. The blended average price of $238.98 sits 3.2% above the current price of $231.48, meaning the insider sold near recent highs before a modest pullback. His cross-ticker track record shows a 50.00% well-timed rate on prior sells (average 90-day return after sales: +4.8%), indicating mixed sell timing historically. At NTRA specifically, 4 of 5 prior measurable trades occurred after 2025-12-12, with the most recent measurable outcome showing +1.5% 30-day return; however, no 90-day outcomes are yet available to assess timing accuracy at this ticker. Against Natera's volatile backdrop—trading 9.0% below its 52-week high of $254.40 while the company reported -$87.5M net income on $592.2M quarterly revenue—the modest 1.5% reduction in holdings carries limited signal strength for a large shareholder.

NTRA President Moshkevich sells 23,498 shares for $5.5M; 5th discretionary sale in 50 days amid 56.8% revenue growth but persistent losses.

Moshkevich Solomon, President of Clinical Diagnostics at Natera, executed 2 separate sales totaling 23,498 shares for $5,515,959.57 on 2026-01-20 and 2026-01-21, reducing his stake by 14.0%. This marks his fifth discretionary open-market sale at NTRA in 50 days (prior sells on 2026-01-02, 2025-12-12, 2025-12-01, and 2025-12-01), establishing a sustained pattern of regular liquidation rather than isolated profit-taking. The company reported 56.8% annual revenue growth and $592.2M in latest quarterly revenue, yet remains unprofitable with net income of $-87.5M and a $33.5B market cap. The repeated sales—at $234.74 blended average against a current price of $242.91—come as the stock trades 4.5% below its 52-week high of $254.40 despite a 26.2% 90-day gain. His cross-ticker track record shows a 60.00% well-timed rate on prior sells, but at this specific ticker his prior 5 trades remain largely unmeasured (only 1 shows a measurable 30-day outcome of +1.5%), offering limited insight into whether the current pattern reflects exit timing or ongoing rebalancing.

NTRA: Moshkevich sells 2,951 shares for $675,621.47; holds 123.5K shares post-sale

Moshkevich Solomon (President, Clinical Diagnostics at Natera) executed 2 separate sales totaling 2,951 shares for $675,621.47 at an average of $228.95, representing a 2.3% reduction in holdings to 123.5K shares. The sale occurred as the stock trades at $248.74, approximately at its 52-week high, having gained 44.5% over the prior 90 days. His same-ticker trade history at NTRA shows 5 prior sells, all clustered around early December 2025, with near-term 30-day returns ranging from -3.4% to -4.4%; however, 90-day outcomes remain unmeasurable for most. His cross-ticker track record shows a 66.67% well-timed sell rate across 20 prior open-market dispositions, though average 90-day returns were marginally positive at +0.5%. Natera remains unprofitable on a full-year basis ($-87.5M net income) despite strong 56.8% annual revenue growth, warranting attention to whether insider activity reflects confidence in near-term execution or selective profit-taking at elevated valuations.

NTRA: President Moshkevich sells 4,692 shares for $1.1M; prior NTRA sales Nov-Dec unresolved, cross-ticker timing mixed

Moshkevich Solomon, President of Clinical Diagnostics, sold 4,692 shares at $230.76, reducing his holding by -3.6% to 126,450 shares. The sale occurred near the stock's 52-week high of $244.55 (within 7.0%), following a strong 30-day run of +11.3% and 90-day rise of +29.6%. His cross-ticker track record shows 20 prior sells with a 69.23% well-timed rate (90-day outcomes), though his average 90-day return after sells was -0.8%. At Natera specifically, he executed four additional sales on 2025-12-01 (outcomes not yet measurable) and a November 2025 sale that posted +19.3% over 30 days, but his prior NTRA sells have shown 0% well-timed at the 90-day mark. The company remains unprofitable (net income $-87.5M on revenue of $592.2M), though it posted +56.8% annual revenue growth. The timing context—selling near a 52-week high during sustained momentum—contrasts with his historical cross-ticker pattern but aligns with immediate post-sale price weakness (current price $227.40, down 1.4% from transaction).

President Moshkevich sold 3,000 NTRA shares in 4 transactions for $714,458.78; stock up 20.2% in 30 days, 43.0% in 90 days

Moshkevich Solomon, President of Clinical Diagnostics at Natera, executed 4 separate sales totaling 3,000 shares for $714,458.78 at blended average price $238.15, reducing his holdings by 2.7% to 109,061 shares. The sales occurred as NTRA stock is up +20.2% over 30 days and +43.0% over 90 days from transaction date, trading near its 52-week high of $238.81. His prior 5 trades at NTRA show mixed results: 2 of 2 measurable 90-day outcomes were well-timed (stock fell after his sales on 2025-07-01), while his most recent 3 sales on 2025-11-03 (completed just 28 days before this filing) show 30-day gains of +19.3% to +20.3%, suggesting those sales were executed into significant strength. The timing pattern warrants observation but does not definitively signal conviction about valuation; the company remains unprofitable with net income of $-87,544,000.00 despite 56.8% annual revenue growth.